DESIGN AND REALISATION OF B/S MODE-BASED COOPERATIVE DESIGN PLATFORM FOR AUV

针对目前自治水下机器人(AUV)设计不支持协同设计的缺陷,构建一个基于B/S模式的AUV协同设计平台。介绍平台的功能和结构,详细论述平台实现的关键技术。利用XML文件实现复杂结构设计流程的信息存储,基于移动Agent技术实现计算任务的调度和执行,并给出基于Aglet平台的移动Agent实现方案。该协同设计平台能够实现AUV多人异地协同设计以及多设计流程的并行执行,提高了AUV设计的效率

一种兆瓦风电齿轮箱前机体结构轻量化设计

以经验为主导的传统齿轮箱箱体的设计方法已逐渐无法满足大兆瓦风电齿轮箱的设计要求。基于此,利用拓扑优化和尺寸优化方法,以轻量化设计为目的,在提高强度和保证刚度的条件下对风电齿轮箱前机体进行结构优化设计。前机体的有限元分析表明,有必要对其结构进行优化设计;基于多位置工况建立前机体的静动耦合拓扑优化模型,根据拓扑优化传力路径获得概念模型;采用响应曲面法对概念模型的关键尺寸进行优化设计,通过筛选法得到最优尺寸。对优化前后前机体的性能进行比较,质量减少12.79%,第一主应力基本不变,刚质比提高7.19%,实现了结构轻量化的目的

分子生物学技术在产甲烷古菌多样性研究中的应用

产甲烷菌在自然界中分布广泛,是一类重要的严格厌氧原核微生物,其参与的产甲烷作用通常发生在厌氧发酵过程的最后一步,可将无机物或有机化合物最终转化成甲烷和二氧化碳。由于产甲烷菌独特的厌氧代谢机制,使其在自然界碳素循环过程中起着重要作用,因此对于产甲烷菌的多样性以及代谢机制的研究越来越受到人们的关注。相对于传统的培养检测方法,分子生物学技术对于产甲烷菌的多样性及其群落结构的检测更为便捷、准确和科学。介绍了产甲烷古菌的系统分类学发展,系统地阐述了产甲烷菌定性和定量的分子生物学检测方法,总结了不同技术在产甲烷菌多样性研究中的最新成果,最后提出多种技术的复合应用将成为研究的热点

2000–2010年中国典型陆地生态系统实际蒸散量和水分利用效率数据集

蒸散是陆地生态系统水分循环和能量平衡的关键过程,水分利用效率是反映生态系统碳水循环间耦合关系的重要指标,二者在生态学、农学、水文学、气候学等多个学科中均具有重要的应用价值。涡度相关法被认为是现今唯一能直接测量生物圈与大气间物质与能量交换通量的标准方法,已成为生态系统尺度碳水交换通量观测的主要方法。本文通过整合中国陆地生态系统通量观测联盟(China FLUX)的长期观测数据和中国区域其他观测站点基于涡度相关法发表的文献数据,构建了一套中国典型陆地生态系统实际蒸散量和水分利用效率数据集。本数据集共有实际蒸散量数据记录143条、水分利用效率数据记录96条,涉及5种生态系统类型45个生态系统,时间跨度为2000–2010年。本数据集可以为陆地生态系统碳水循环、生态系统管理和评估、全球变化等相关领域的研究提供数据支持

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

Prediction of Energy Resolution in the JUNO Experiment

International audienceThis paper presents the energy resolution study in the JUNO experiment, incorporating the latest knowledge acquired during the detector construction phase. The determination of neutrino mass ordering in JUNO requires an exceptional energy resolution better than 3% at 1 MeV. To achieve this ambitious goal, significant efforts have been undertaken in the design and production of the key components of the JUNO detector. Various factors affecting the detection of inverse beta decay signals have an impact on the energy resolution, extending beyond the statistical fluctuations of the detected number of photons, such as the properties of liquid scintillator, performance of photomultiplier tubes, and the energy reconstruction algorithm. To account for these effects, a full JUNO simulation and reconstruction approach is employed. This enables the modeling of all relevant effects and the evaluation of associated inputs to accurately estimate the energy resolution. The study reveals an energy resolution of 2.95% at 1 MeV. Furthermore, the study assesses the contribution of major effects to the overall energy resolution budget. This analysis serves as a reference for interpreting future measurements of energy resolution during JUNO data taking. Moreover, it provides a guideline in comprehending the energy resolution characteristics of liquid scintillator-based detectors